Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

111 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Characteristics and treatment of Multiple Sclerosis-related trigeminal neuralgia: An Italian multi-centre study.
Ferraro D, Annovazzi P, Moccia M, Lanzillo R, De Luca G, Nociti V, Fantozzi R, Paolicelli D, Ragonese P, Gajofatto A, Boffa L, Cavalla P, Lo Fermo S, Buscarinu MC, Lorefice L, Cordioli C, Calabrese M, Gallo A, Pinardi F, Tortorella C, Di Filippo M, Camera V, Maniscalco GT, Radaelli M, Buttari F, Tomassini V, Cocco E, Gasperini C, Solaro C; RIREMS (Rising Researchers in Multiple Sclerosis). Ferraro D, et al. Among authors: boffa l. Mult Scler Relat Disord. 2020 Jan;37:101461. doi: 10.1016/j.msard.2019.101461. Epub 2019 Oct 19. Mult Scler Relat Disord. 2020. PMID: 31678859
A cross-sectional, multicentre study of the therapeutic management of multiple sclerosis relapses in Italy.
Annovazzi P, Tomassini V, Bodini B, Boffa L, Calabrese M, Cocco E, Cordioli C, De Luca G, Frisullo G, Gallo A, Malucchi S, Paolicelli D, Pesci I, Radaelli M, Ragonese P, Roccatagliata L, Tortorella C, Vercellino M, Zipoli V, Gasperini C, Rodegher M, Solaro C. Annovazzi P, et al. Among authors: boffa l. Neurol Sci. 2013 Feb;34(2):197-203. doi: 10.1007/s10072-012-0981-5. Epub 2012 Mar 11. Neurol Sci. 2013. PMID: 22407022
Reversible hyporegenerative anemia during natalizumab treatment.
Monteleone F, Buccisano F, Boffa L, Buttari F, Di Veroli A, Borriello G, Rossi S, Centonze D. Monteleone F, et al. Among authors: boffa l. Mult Scler. 2015 Feb;21(2):257-8. doi: 10.1177/1352458514546516. Epub 2014 Sep 3. Mult Scler. 2015. PMID: 25186208 No abstract available.
Management of flu-like syndrome with cetirizine in patients with relapsing-remitting multiple sclerosis during therapy with interferon beta: Results of a randomized, cross-over, placebo-controlled pilot study.
Landi D, Albanese M, Buttari F, Monteleone F, Boffa L, Rossi S, Motta C, Puma E, Centonze D. Landi D, et al. Among authors: boffa l. PLoS One. 2017 Jul 7;12(7):e0165415. doi: 10.1371/journal.pone.0165415. eCollection 2017. PLoS One. 2017. PMID: 28686675 Free PMC article. Clinical Trial.
A multicentRE observational analysiS of PErsistenCe to Treatment in the new multiple sclerosis era: the RESPECT study.
Lanzillo R, Prosperini L, Gasperini C, Moccia M, Fantozzi R, Tortorella C, Nociti V, Annovazzi P, Cavalla P, Radaelli M, Malucchi S, Clerici VT, Boffa L, Buttari F, Ragonese P, Maniscalco GT, Di Filippo M, Buscarinu MC, Pinardi F, Gallo A, Coghe G, Pesci I, Laroni A, Gajofatto A, Calabrese M, Tomassini V, Cocco E, Solaro C; R.I.Re.MS study group. Lanzillo R, et al. Among authors: boffa l. J Neurol. 2018 May;265(5):1174-1183. doi: 10.1007/s00415-018-8831-x. Epub 2018 Mar 16. J Neurol. 2018. PMID: 29549468
Abortion induces reactivation of inflammation in relapsing-remitting multiple sclerosis.
Landi D, Ragonese P, Prosperini L, Nociti V, Haggiag S, Cortese A, Fantozzi R, Pontecorvo S, Ferraro E, Buscarinu MC, Mataluni G, Monteleone F, Salvetti M, Di Battista G, Francia A, Millefiorini E, Gasperini C, Mirabella M, Salemi G, Boffa L, Pozzilli C, Centonze D, Marfia GA. Landi D, et al. Among authors: boffa l. J Neurol Neurosurg Psychiatry. 2018 Dec;89(12):1272-1278. doi: 10.1136/jnnp-2018-318468. Epub 2018 Jul 3. J Neurol Neurosurg Psychiatry. 2018. PMID: 29970387
Safety and Efficacy of Dimethyl Fumarate in Multiple Sclerosis: An Italian, Multicenter, Real-World Study.
Mirabella M, Prosperini L, Lucchini M, Boffa L, Borriello G, Buscarinu MC, Centonze D, Cortese A, De Fino C, De Giglio L, Elia G, Fantozzi R, Ferraro E, Francia A, Galgani S, Gasperini C, Haggiag S, Landi D, Marfia GA, Millefiorini E, Monteleone F, Nociti V, Salvetti M, Sgarlata E, Pozzilli C. Mirabella M, et al. Among authors: boffa l. CNS Drugs. 2018 Oct;32(10):963-970. doi: 10.1007/s40263-018-0543-3. CNS Drugs. 2018. PMID: 30022464
No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study.
Prosperini L, Annovazzi P, Boffa L, Buscarinu MC, Gallo A, Matta M, Moiola L, Musu L, Perini P, Avolio C, Barcella V, Bianco A, Farina D, Ferraro E, Pontecorvo S, Granella F, Grimaldi LME, Laroni A, Lus G, Patti F, Pucci E, Pasca M, Sarchielli P; Italian Alemtuzumab Study Group. Prosperini L, et al. Among authors: boffa l. J Neurol. 2018 Dec;265(12):2851-2860. doi: 10.1007/s00415-018-9070-x. Epub 2018 Sep 26. J Neurol. 2018. PMID: 30259178
111 results